pioglitazone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 296 Diseases   92 Trials   92 Trials   3449 News 


«12345678910111213...4849»
  • ||||||||||  pioglitazone / Generic mfg.
    Preclinical, Journal:  Multispectral Optoacoustic Tomography (MSOT): Monitoring Neurovascular Changes in a Mouse Repetitive Traumatic Brain Injury Model. (Pubmed Central) -  Jun 14, 2023   
    Mice were subjected to rTBI or sham via controlled cortical impact and administered pioglitazone (PG) or vehicle...In comparison to standard methods of tracking inflammation and BBB disruption, MSOT can be used multiple times throughout the course of injury without the need for surgery. Thus, MSOT is especially useful in research of rTBI models for screening therapeutics, and with further technological improvements may be extended for use in rTBI patients.
  • ||||||||||  pioglitazone / Generic mfg.
    Trial completion, Enrollment change:  Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19 (clinicaltrials.gov) -  May 31, 2023   
    P4,  N=8, Completed, 
    Sacubitril-valsartan may be an effective modulator of diabetes mellitus-associated metabolic aberration, superiorly compared to valsartan only. Recruiting --> Completed | N=76 --> 8
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Neuron stem cell NLRP6 sustains hippocampal neurogenesis to resist stress-induced depression. (Pubmed Central) -  May 30, 2023   
    Pioglitazone, a well-known clinical drug, up-regulated NLRP6 expression to inhibit ECRG4 expression in its protection against corticosterone-induced NSC mitochondrial dysfunction and proliferation restriction. In conclusion, this study demonstrates that NLRP6 is essential to maintain mitochondrial homeostasis and proliferation in NSCs, and identifies NLRP6 as a promising therapeutic target for hippocampal neurogenesis decline linked to depression.
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change, Trial withdrawal:  Insulin Resistance Following ADT for Prostate CA (clinicaltrials.gov) -  May 15, 2023   
    P1,  N=0, Withdrawn, 
    agonist could induce PD-L1 autophagic degradation resulting in increased colorectal tumor immunotherapy. N=44 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  pioglitazone / Generic mfg.
    Trial completion date, Trial primary completion date:  Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients (clinicaltrials.gov) -  May 10, 2023   
    P4,  N=28, Recruiting, 
    There is a need for further studies on the cardioprotective role of lobeglitazone, a novel thiazolidinedione. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  pioglitazone / Generic mfg.
    Preclinical, Journal:  Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats. (Pubmed Central) -  May 1, 2023   
    The results of H&E staining and Western blot revealed that combined treatment with PIO and mFGF21 significantly decreased hepatic fat accumulation in NAFLD rats by activating the SHP1/AMPK signaling pathway. Our finding collectively demonstrated that PIO and mFGF21 combination therapy could synergistically ameliorate metabolic disorders in NAFLD rats.
  • ||||||||||  pioglitazone / Generic mfg.
    Review, Journal:  Effects of Hypolipidemic Drugs on Psoriasis. (Pubmed Central) -  Apr 28, 2023   
    In recent years, many new drugs were found to normalize the lipid profile in patients with psoriasis: glitazones (pioglitazone, troglitazone), and glucagon-like peptide-1 (GLP-1) receptor agonists...We were browsing PubMed and Google Scholar until the beginning of December. The systematic review includes 41 eligible original articles.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. (Pubmed Central) -  Apr 24, 2023   
    In results, the pioglitazone group (n = 17,388) exhibited a lower rate (per person-years) of major advanced cardiovascular events MACCE (2.76% vs. 3.03%, hazard ratio [HR]: 0.91, 95% confidence interval [CI]: 0.87-0.95), new- diagnosis dementia (1.32% vs. 1.46%, HR: 0.91, 95% CI: 0.84-0.98) but a higher rate of new-diagnosis bone fractures (5.37% vs. 4.47%, HR: 1.24, 95% CI: 1.19-1.28) than the non-pioglitazone group (n = 174,549). In conclusion, using pioglitazone may reduce the risks of MACCE and dementia but increases the probability of bone fractures in the elderly DM population.
  • ||||||||||  pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
    Journal, Machine learning:  Microscopic image-based classification of adipocyte differentiation by machine learning. (Pubmed Central) -  Apr 11, 2023   
    agonists, and that our classifier and model can accurately estimate drug action points and would be suitable for evaluating the stage/state of individual cells during differentiation or disease progression. The incorporation of both biochemical and morphological information derived from immunofluorescence image of cells and so overcomes limitations of current models.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate ( (Poster Halls B-C; [Board No. 895]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1470;    
    In conclusion, long-term therapy with Empagliflozin leads to elevated ?-OHB in 25% of T2DM and it was associated with poor glycemic control. Concomitant insulin or pioglitazone therapy did not alter plasma ?-OHB concentration.
  • ||||||||||  TLC-3595 / OrsoBio
    Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats (Poster Halls B-C; [Board No. 849]) -  Apr 10, 2023 - Abstract #ADA2023ADA_1415;    
    TLC-3595 reduced IMCL, improved IS, and delayed T2D progression comparable to Pio in ZDF rats. These data provide strong rationale for evaluation of TLC-3595 to treat insulin resistance and T2D.
  • ||||||||||  pioglitazone / Generic mfg.
    Gaps in the Use of Evidence-Based Diabetes Medications for NASH (Poster Halls B-C; [Board No. 1359]) -  Apr 10, 2023 - Abstract #ADA2023ADA_726;    
    Use of pioglitazone was particularly low, despite its low cost and longstanding evidence for use in NASH. Future studies should explore reasons for underuse of these evidence-based T2D medications in NASH, and whether this is changing over time with growing evidence supporting their use in NASH.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Safer pioglitazone alternative is effective. (Pubmed Central) -  Mar 31, 2023   
    Future studies should explore reasons for underuse of these evidence-based T2D medications in NASH, and whether this is changing over time with growing evidence supporting their use in NASH. No abstract available
  • ||||||||||  pioglitazone / Generic mfg., doxorubicin hydrochloride / Generic mfg., fenofibrate / Generic mfg.
    Preclinical, Journal:  Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats. (Pubmed Central) -  Mar 30, 2023   
    The above-mentioned biochemical markers were affirmed by histological assessment. In conclusion, fenofibrate, pioglitazone, and their combination possess potential prophylactic effects against doxorubicin-induced renal injury through modulation of p38-MAPK/NF-?B p65 pathway with superiority to the combination.
  • ||||||||||  Sunvepra (asunaprevir) / BMS, Tracleer (bosentan) / J&J, Roche
    Preclinical, Journal:  Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats. (Pubmed Central) -  Mar 30, 2023   
    Ketoconazole unexpectedly decreased systemic and liver gadoxetate AUCs; the remaining drugs investigated (asunaprevir, bosentan, and pioglitazone) caused marginal changes...PBPK modelling correctly predicted changes in gadoxetate systemic AUCR, whereas underprediction of decreases in liver AUCs was evident. The current study illustrates the modelling framework and integration of liver imaging data, PBPK, and tracer-kinetic models for prospective quantification of hepatic transporter-mediated DDI in humans.
  • ||||||||||  mitoglitazone (MSDC-0160) / Metabolic Solutions
    Journal:  Mitoglitazone ameliorates renal ischemia/reperfusion injury by inhibiting ferroptosis via targeting mitoNEET. (Pubmed Central) -  Mar 28, 2023   
    Mechanistically, molecular docking and surface plasmon resonance experiments demonstrated that MGZ exhibited a high binding affinity with the mitochondrial outer membrane protein mitoNEET. Collectively, our findings indicated the renal protective effect of MGZ was closely linked to regulating the mitoNEET-mediated ferroptosis pathway, thus offering potential therapeutic strategies for ameliorating I/R injuries.